MINI LONG - NOVO-NORDISK B | Real-time Bid/Ask 01:08:14 27/06/2024 pm IST | ||
| 17.09 EUR / 17.1 EUR | -0.78% |
|
| Current month | +14.79% | ||
| 1 month | +11.81% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 26/24/26 | 17.23 | -2.27% |
| 25/24/25 | 17.63 | +6.01% |
| 24/24/24 | 16.63 | -1.31% |
| 21/24/21 | 16.85 | +1.20% |
| 20/24/20 | 16.65 | +0.85% |
Delayed Quote Börse Stuttgart
Last update June 26, 2024 at 10:03 pm IST
More quotesStatic data
| Product type | Knock-Out sin Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MD8ESV |
| ISIN | DE000MD8ESV3 |
| Date issued | 22/09/2022 |
| Strike | 365.4 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 1.18 € |
| Emission volume | N/A |
| Settlement | Por diferencias |
| Currency | EUR |
Technical Indicators
| Highest since issue | 17.66 € |
|---|---|
| Lowest since issue | 1.13 € |
| Spread | 0.01 € |
| Spread % | 0.06% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,007
DKK
Average target price
938.1
DKK
Spread / Average Target
-6.84%
- Stock Market
- Certificates
- Certificat
